Dual GIP / GLP-1 Agonist — 10mg/vial
$160.00 AUD
First-in-class "twincretin" — SURMOUNT-1: up to 22.5% weight reduction.
⚠️ Currently Out of Stock
Sign up to be notified when Tirzepatide is back in stock.
Browse Other Products →
💧 Need BAC water? 30mL bacteriostatic water available — $21.90 ($13 less than AU competitors). Add to your order.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist, coined a "twincretin." Developed by Eli Lilly and approved as Mounjaro, the landmark SURMOUNT-1 Phase 3 trial demonstrated average weight loss of 22.5% at 72 weeks at the 15 mg dose — the most significant pharmacologically-induced weight reduction demonstrated in a randomised controlled trial at the time of publication.
As a 39-amino-acid molecule with a modified C20 fatty diacid chain, Tirzepatide achieves an approximately 5-day half-life enabling once-weekly subcutaneous dosing. Its dual GIP/GLP-1 mechanism creates synergistic effects exceeding pure GLP-1 agonism, making it one of the most studied metabolic research compounds of the decade.
"FOR RESEARCH USE ONLY. This information is provided for scientific and educational purposes only. It does not constitute medical advice or a recommendation for human use."
| Compound | Tirzepatide |
| Form | Lyophilized powder |
| Dosage | 10mg/vial |
| Purity | 99%+ (HPLC verified) |
| Testing | Third-party HPLC + MS |
| Storage | 2-8°C (refrigerated) |
| Origin | GMP facility |
Tirzepatide is a single 39-amino-acid molecule that acts as a co-agonist at both the GIP receptor (GIPR) and GLP-1 receptor (GLP1R). Simultaneous GIPR and GLP1R activation creates synergistic effects on insulin secretion, glucagon suppression, gastric emptying, appetite reduction, and energy expenditure that exceed pure GLP-1 agonism alone.
Its modified C20 fatty diacid chain provides an approximate 5-day half-life, enabling once-weekly subcutaneous dosing in clinical protocols. The dual mechanism distinguishes it from semaglutide (pure GLP-1), and positions it as the intermediate step between single-agonist and triple-agonist (Retatrutide) metabolic research compounds.
Every batch independently tested via HPLC and Mass Spectrometry. COAs published on site.
Based in Australia with express shipping nationwide. Discreet, temperature-controlled packaging.
We beat any Australian competitor's pricing by 5%. Crypto, card, and bank transfer accepted.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Targets | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Weight Reduction | ~22.5% (SURMOUNT-1) | ~24.2% (TRIUMPH-2) |
| Additional Action | Dual incretin synergy | + Increased energy expenditure |
| Status | Currently out of stock | In stock |
Researchers may wish to consider Retatrutide (triple agonist, in stock) as an alternative.
Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist ("twincretin"). The additional GIP receptor agonism provides synergistic effects on weight reduction and metabolic control. SURMOUNT-1 showed 22.5% weight reduction vs semaglutide's ~15% in STEP trials, though direct head-to-head comparisons vary by protocol.
The SURMOUNT-1 protocol used a 20-week dose escalation: starting at 2.5 mg/week, escalating every 4 weeks through 5, 7.5, 10, 12.5 mg to target doses of 5, 10, or 15 mg/week. Subcutaneous injection once weekly due to the 5-day half-life conferred by the C20 fatty diacid chain modification.
Tirzepatide is legal to purchase for legitimate research purposes in Australia. It is not a scheduled substance when intended for laboratory research use only. All sales are strictly for research purposes — not for human or veterinary consumption.
Retatrutide is our in-stock GLP-1 research peptide and offers a broader triple agonist mechanism (GLP-1 + GIP + glucagon). Both compounds share similar research applications. Sign up for the Tirzepatide notify list on the homepage to be alerted when stock returns.
Enter your email and we'll alert you the moment it's back in stock.